Collaborative for Effective Prescription Opioid Policies

Similar documents
Wednesday, June 21, Dear Chairmen and Ranking Members:

August 30, Washington, DC Washington, DC Dear Chairman Cochran, Chairman Blunt, Vice Chairman Leahy and Ranking Member Murray:

The National Association of State Alcohol and Drug Abuse Directors (NASADAD) FY 2018 Appropriations

Labor, Health and Human Services & Education Labor, Health and Human Services & Education

September 1, The Honorable Tom Price, MD Secretary Department of Health and Human Services 200 Independence Avenue SW Washington, DC 20201

Labor, Health and Human Services & Education Labor, Health and Human Services & Education

Public Health Federal Funding Request to Address the Opioid Epidemic

BJA Harold Rogers PDMP National Meeting on Data Driven Multi-Disciplinary Approaches to Reducing Rx Abuse

The Honorable Mitch McConnell The Honorable Harry Reid

Successful Prevention Strategies to Address the Opioid Crises

House Committee on Energy and Commerce House Committee on Energy and Commerce. Washington, DC Washington, DC 20515

STATEMENT. of the. American Medical Association. for the Record. House Committee on Energy and Commerce

Strategies to Improve Viral Hepatitis Prevention, Care and Treatment through Appropriations. Emily McCloskey USCA October 3, 2014

Washington, D.C Washington, D.C

American Academy of Pain Medicine American Pain Society American Society of Anesthesiologists

ASTHO President s Challenge 15 x 15: Reduce Prescription Drug

FY2019 Labor, Health and Human Services, Education Appropriations Summary

Pennsylvania s Opioid Crisis: Data and Strategies to Combat It

The National Association of State Alcohol and Drug Abuse Directors (NASADAD) FY 2018 Appropriations

National Strategies for Local Solutions

The National Association of State Alcohol and Drug Abuse Directors (NASADAD) FY 2019 Budget and Appropriations

Data-Driven Prevention Initiative

Washington, DC Washington, DC Washington, DC Washington, DC 20510

STATE & FEDERAL EFFORTS TO COMBAT THE OPIOID EPIDEMIC & IMPACT ON COMPLIANCE PROGRAMS GRACE E. REBLING OSBORN MALEDON P.A.

Performance of North Carolina's System for Monitoring Prescription Drug Abuse. Session Law , Section 12F.16.(q)

FY19 Labor, Health and Human Services, and Education Appropriations Bill

QUARTERLY PROVIDER MEETING MARCH 9, 2017 SUZANNE BORYS, ED.D.

Strategies for Federal Agencies

The National Association of State Alcohol and Drug Abuse Directors (NASADAD) FY 2019 Appropriations

Do you CARA? A Deep Dive Into the Comprehensive Addiction and Recovery Act Joel White, President

Opioid Response Package Awaits President s Signature Trinity Tomsic

1025 Connecticut Avenue NW, Suite 605 * Washington, DC * (202) * Fax: (202)

Implementing the 2017 President s Challenge: Primary, Secondary & Tertiary Prevention of Addiction & Substance Misuse

Michael M. Miller, MD, FASAM, FAPA

Building a Comprehensive, Community-driven Prevention Approach to the Opioid Crisis in Maine

The National Association of State Alcohol and Drug Abuse Directors (NASADAD) FY 2018 Appropriations

March XX, Washington, DC Washington, DC Washington, DC Washington, DC 20515

April 24, testimony. The AGS is a non-profit organization of nearly 6,000 geriatrics healthcare

CDC Coalition. Washington, DC Washington, DC Washington, DC Washington, DC 20515

SAMHSA: A Public Health Agency

Assessing Opioid Misuse and Overdose Using Prescription Drug Monitoring Programs (PDMP) and Other Data Sources

Implementation: Public Hearing: Request for Comments (FDA-2017-N-6502)

Although PDMPs are separately managed and maintained by each state or jurisdiction, the national network facilitates more uniformity among states.

Data-Driven Multidisciplinary Approaches to Reduce Prescription Drug Abuse in Kentucky

BJA COAP Category 6 Quarterly Webinar November 29, 2018

Opioid Crisis: HHS Strategy and Advancing Pain Management

Suicide Prevention Strategic Plan

Submitted to the House Energy and Commerce Committee. Federal Efforts to Combat the Opioid Crisis

Opioid Use and Misuse: History, Trends, And The Oregon Opioid Initiative

Vanila M Singh, MD MACM Chief Medical Officer Office of the Assistant Secretary for Health U.S. Department of Health and Human Services

OVERVIEW OF STATE OPIOID POLICY AND LEGISLATION AMBER WIDGERY & ALISON LAWRENCE JUNE 2018

FY2019 Labor, Health and Human Services, Education Appropriations Summary

CDC s Approach to Addressing the Opioid Overdose Epidemic

Addressing Substance Use Disorder and the Opioid Epidemic in North Carolina

INTER-AMERICAN DRUG ABUSE CONTROL COMMISSION C I C A D

Meth and Opioid Abuse Prevention Efforts

Centers for Disease Control and Prevention (CDC) Coalition C/o American Public Health Association 800 I Street NW Washington, DC,

NACo OPIOID LEGISLATIVE ANALYSIS Comparison of House and Senate Opioid Legislative Packages

SAMHSA FY 2017 Discretionary Grant Forecast

OPIOID WORKGROUP LEADERSHIP TEAM

Opioid Overview Admiral Brett P. Giroir, M.D.

Prevention Science and the Opioid Epidemic

National Academy of Medicine Action Collaborative: Countering the US Opioid Epidemic

Risk Classification Modeling to Combat Opioid Abuse

THE 21ST CENTURY CURES ACT: TACKLING MENTAL HEALTH FROM THE INSIDE OUT

Tom Williams, MD Chief Medical Officer Director of the Division of Public Health Nebraska Department of Health and Human Services

Health Care Reform: Implications for Public Health. Susan Polan, PhD. American University Next steps in Health Reform 2017

The Future of Prevention: Addressing the Prescription Drug Abuse and the Opioid/Heroin Epidemic in our Country

Opioid Overdose in Oregon Report to the Legislature

Challenges for U.S. Attorneys Offices (USAO) in Opioid Cases

Comprehensive Substance Abuse Strategic Action Plan

ANALYSIS OF THE ADMINISTRATION S FISCAL YEAR 2004 BUDGET FOR THE CENTERS FOR DISEASE CONTROL AND PREVENTION

20% A Holistic Approach Built on Evidence OF U.S. ADULTS EXPERIENCE MENTAL ILLNESS EACH YEAR

Opioid Abuse. in Rural Minnesota. County Farm Bureau Resource Guide

Washington State PMP Data Mapping Project

Kansas Department of Health and Environment (KDHE) Kansas Data-Driven Prevention Initiative Request for Proposal (RFP) Fiscal Year 2019

Testimony of the Association for Professionals in Infection Control and Epidemiology (APIC) and

Opportunities for Engaging Partners to Prevent Opioid Overdose-related Deaths

FACT SHEET: Federal Parity Task Force Takes Steps to Strengthen Insurance Coverage for Mental Health and Substance Use Disorders

HHSC LAR Request. Substance Abuse Disorder Coalition. Contact Person: Will Francis Members:

Steve Daviss MD DFAPA Senior Medical Advisor Office of the Chief Medical Officer

SAFE OPIOID PRESCRIBING C.U.R.E.S. PROGRAM

ADDRESSING THE OPIOID EPIDEMIC. Joint principles of the following organizations representing front-line physicians

ACCG Mental Health Summit

OPIOID INITIATIVE SMART GOALS AND OBJECTIVES Four Pillar Approach

Prescription Opioid Overdose in Oregon: A public health perspective

HOPE Agenda. Heroin, Opioid Prevention & Education WISCONSIN STATE REPRESENTATIVE JOHN NYGREN ASSEMBLY DISTRICT 89

PDMP Track: Linking and Mapping PDMP Data. Gillian Leichtling Acumentra Health Chris Baumgartner, WA State Dept. of Health

VIRGINIA S OPIOID & HEROIN OVERDOSE EPIDEMIC

State Action to Prevent and

General Session September 25: Directly following the opening session:

MANAGING THE COSTS OF THE OPIOID EPIDEMIC IN WISCONSIN. State Senator Alberta Darling

January 17, Re: Secretary s Advisory Committee on National Health Promotion and Disease Prevention Objectives for Healthy People 2030

State Targeted Opioid Response Initiative (STORI) Fee-for-Service (FFS) Open Enrollment

Generation Rx: The Abuse of Prescription and Over-the-Counter Drugs

CDC Coalition. Dear Chairmen Frelinghuysen and Cole and Ranking Members Lowey and DeLauro:

FY2018 Labor, Health and Human Services, Education Appropriations Summary

Module 6: Substance Use

Cardinal Health s Commitment to Opioid Anti-Diversion, Education and Misuse Prevention

SRSLY Strategic Plan I. Introduction Community Needs Assessment & Strategic Planning

Transcription:

The Honorable Richard Shelby Committee on Appropriations 304 Senate Office Building The Honorable Roy Blunt Subcommittee on Labor, Health and Human Services, Education and Related Agencies 260 Russell Senate Office Building The Honorable Jerry Moran Subcommittee on Commerce, Justice, Science and Related Agencies 521 Dirksen Senate Office Building The Honorable James Lankford Subcommittee on Financial Services and General Government 316 Hart Senate Office Building The Honorable Patrick Leahy Committee on Appropriations 437 Russell Senate Office Building The Honorable Patty Murray Subcommittee on Labor, Health and Human Services, Education and Related Agencies 154 Russell Senate Office Building The Honorable Jeanne Shaheen Subcommittee on Commerce, Justice, Science and Related Agencies 506 Hart Senate Office Building The Honorable Christopher Coons Subcommittee on Financial Services and General Government 127A Russell Senate Office Building Wednesday, June 13, 2018 Dear Chairmen and s: As members of the (CEPOP; www.cepoponline.org), we are writing in support of robust funding for the below programs to address the opioid epidemic. Together, these programs will increase access to prevention, treatment and recovery services and will help save lives. CEPOP is a diverse group of stakeholders interested in the manufacture, distribution and appropriate use of opioid medications, who have joined together to work toward a comprehensive and balanced policy strategy to prevent misuse and promote treatment and recovery options. We support effective programs, Page 1 of 5

strategies and policies to help prevent prescription painkiller misuse and overdose, while ensuring patients' access to safe effective pain treatment. The opioid epidemic continues to devastate American communities, and we must invest in prevention as well as treatment if we are to turn the tide. Opioid overdoses (including prescription opioids, heroin and fentanyl) led to the deaths of more than 42,000 people in 2016, more than any year on record. That is five times higher than the number of opioid overdose deaths in 1999. An average of 15 people a day die from an opioid overdose. We appreciate the Committee s ongoing commitment to providing much needed resources to address the opioid epidemic, including significant new resources made available in the FY 2018 Omnibus Appropriations Act and ongoing efforts to fund the comprehensive programs authorized by the Comprehensive Addiction and Recovery Act (CARA). As you work to craft FY 2019 appropriations legislation, we urge you to fully fund the programs authorized in CARA, in all three subcommittees, as well as the spectrum of existing prevention, treatment and recovery programs that are critical to ensuring a comprehensive response to the substance misuse epidemic. Our recommendations include: Labor-HHS-Education and Related Agencies Appropriations Act (LHHS) Substance Abuse and Mental Health Services Administration (SAMHSA) 1 : Substance Abuse Prevention and Treatment Block Grant: The Substance Abuse Prevention and Treatment Block Grant Program (SAPTBG) distributes funds to 60 eligible states, territories, the District of Columbia, and the Red Lake Band of Chippewa Indians of Minnesota to plan, carry out, and evaluate substance abuse prevention, treatment and recovery support services provided for individuals, families, and communities impacted by substance abuse and substance use disorders (SUD). While SAPTBG received a much needed increase in FY16, it had been flat funded for the past several years and has not kept up with inflation, despite the growth in need as the opioid epidemic continues. We urge the Committee to provide an increase for the SAPTBG in FY19 over the FY18 level of $1.85 billion so that states can do more to meet the increasing need for prevention, treatment and recovery strategies and services. Center for Substance Abuse Treatment: SAMHSA s Center for Substance Abuse Treatment (CSAT) is dedicated to expanding access to high quality treatment and recovery services, including access to Medication Assisted Treatment when appropriate. According to the National Survey on Drug Use and Health, 21.5 million people aged 12 or older needed treatment for an alcohol or illicit drug use problem in 2014. During the same year, more than 4 million received treatment for such a problem. That means 17.5 million Americans needed but did not receive services for a substance use problem. We urge the Committee to provide, at a minimum, $405.4 million (level funding) for CSAT. Center for Substance Abuse Prevention: SAMHSA s Center for Substance Abuse Prevention (CSAP) brings evidence based prevention programs and strategies to every state and sub-state 1 All requested levels of funding should not be taken out of other existing Substance Abuse and Mental Health Services Administration line items that support individuals living with mental illness or substance abuse, including those with co-occurring disorders. Page 2 of 5

regions nationwide. Its discretionary grant programs target states, communities, organizations, workplaces and families to promote resiliency, promote protective factors, reduce risk factors for substance use, and provide grants for overdose reversal. The President s budget would seriously impede efforts to prevent substance use, to stop and delay initiation. We urge the Committee to provide, at a minimum, $248.2 million (level funding) for CSAP. We cannot afford to reduce access to effective prevention programs and strategies. State Targeted Response (STR) to the Opioid Crisis Grants: In the 21 st Century Cures Act, Congress authorized a $1 billion account ($500 million in FY17 and $500 million in FY18) for the State response to the opioid abuse crisis, with another billion made available through the FY18 budget agreement. The program seeks to address the opioid crisis by awarding grants to States to enhance treatment, prevention, recovery and overdose reversal programs and services. Grantees were required to use epidemiological data to outline gaps in services, utilize evidencebased implementation strategies, and report progress on categories such as reductions in opioidrelated overdose deaths, increased access to treatment and others. We urge the Committee to again appropriate $1.5 billion in FY19 (level funding) for the STR grants. Centers for Disease Control and Prevention (CDC), Injury Center: The CDC uses data and prevention strategies to help track trends in the epidemic, identify problem areas, and help states strengthen and evaluate prevention efforts. CDC is also equipping health care providers with data and tools needed for appropriate opioid prescribing. Through the Opioid Prevention in States effort, CDC works with 45 states and the District of Columbia. CDC provides scientific expertise, enhanced surveillance activities, and support resources to quickly report fatal and non-fatal overdoses; identifies hot spots and responds with targeted resources; and identifies risk factors for overdoses and shares data to improve prevention responses. We are pleased that as part of the FY18 Omnibus appropriations package, the CDC received a $350 million funding increase, with specific mention around CDC promotion of PDMP use and expansion of efforts to make PDMPs more interconnected, real-time, and usable for public health surveillance and clinical decision making. In FY19 we request $625 million ($200 million increase), which would include additional funding from that FY18 increase. Office of the Surgeon General: More than half of children, across all socioeconomic groups, experience an adverse childhood experience (ACE) such as physical abuse, substance misuse in the household, sexual abuse, and parental divorce or separation. The more ACEs experienced, the higher the likelihood for a range of negative health and behavioral health consequences throughout their life, including substance misuse. Understanding these connections can help us better implement evidence-based substance misuse prevention programs. We request that the Committee provide $2 million for the Office of the Surgeon General to develop a report on the connection between ACES, future substance misuse, and other health conditions, in collaboration with the CDC, National Institutes of Health, and other agencies as appropriate. Commerce-Justice-Science Appropriations Act Hal Rogers PDMP Grant Program: PDMPs are a critical tool for addressing prescription drug abuse, yet PDMP capabilities vary widely by state. The Rogers PDMP Program is a discretionary, competitive grant program administered through the Justice Department, Bureau of Justice Assistance. The Rogers grants are intended to enhance the capacity of regulatory and law enforcement agencies and public health officials to collect and analyze controlled substance prescription data and other scheduled chemical Page 3 of 5

products through a centralized database administered by an authorized state agency. We recommend $30 million (level funding) for the Rogers PDMP program in FY19. Edward Byrne Memorial Justice Assistance Grant (JAG) Program: The JAG program provides states and local governments with funding necessary to support a range of program areas including law enforcement, prosecution and court programs including indigent defense, prevention and education programs, corrections and community corrections, drug treatment and enforcement, and planning, evaluation and technology improvement programs. States are investing in strategies to improve outcomes for justice-involved individuals with mental illness and substance use disorders. Yet funding for the Byrne JAG program has dropped by about one-third in recent years. We urge Congress to begin to restore funding to the Byrne JAG program and recommend at least $415 million for this critical program, with no carve outs. Drug Enforcement Administration (DEA): The DEA is a key federal agency in the effort to reverse the opioid epidemic for prescription drug abuse, misuse, and diversion. CEPOP supports the agency s engagement in the National Take-Back Initiative, as well as the innovative 360 Strategy program. We recommend that the Committee include, at minimum, the FY 2017 appropriated levels, plus any enhancements proposed in the Administration s FY 2018 budget request, for these programs in the appropriations bill for the coming year. Financial Services and General Government Appropriations Act Drug-Free Communities Grant Program: The Drug-Free Communities Grant Program (DFC) is administered by the Office of National Drug Control Policy and provides support for communities to identify and respond to local drug and underage drinking problems. DFC grantees have reduced drug use and abuse in communities throughout the country to levels lower than national averages because they are organized, data driven and take a comprehensive, multi-sector approach to solving and addressing drug issues. DFC coalitions are uniquely situated to deal with emerging drug trends, such as prescription drug abuse, because they have the infrastructure in place to effectively address any drug related issues within their communities. We recommend $101 million for the DFC in FY19. Community-Based Coalition Enhancement Grants: CARA s prevention provision, Section 103, is purposefully drafted to build on the effective DFC community-based infrastructure to help communities address local drug crises. DFC grantees are maximally prepared and proven effective in preventing and addressing all alcohol, tobacco, and drug issues, as they engage in evidence-based, comprehensive, multicomponent strategies across all community sectors to achieve population-level decreases in substance use rates. Providing enhancement grants to existing DFC grantees to specifically deal with opioid abuse is critical because DFC grantee coalitions already have the necessary infrastructure and expertise to most cost-effectively prevent prescription drug misuse and abuse. We request $5 million, the full authorization, for this program in FY19. Together, these programs will help expand prevention efforts to reduce opioid misuse and promote access to life saving treatment and recovery services and rescue medications. A comprehensive approach is the one way we will reverse the substance misuse epidemic. Thank you for your consideration. Page 4 of 5

Sincerely, Community Anti-Drug Coalitions of America, CEPOP Co-Convener and Steering Committee Member The Honorable Mary Bono, CEPOP Co-Convener and Steering Committee Member Trust for America s Health, CEPOP Co-Convener and Steering Committee Member American Public Health Association AmerisourceBergen Corporation CADA of Northwest Louisiana California Consortium of Addiction Programs & Professionals (CCAPP) DuPage County Health Department Hazelden Betty Ford Foundation IC & RC Illinois Association of Behavioral Health Kentucky Office of Drug Control Policy, CEPOP Steering Committee Member Mallinckrodt Pharmaceuticals National Association of County and City Health Officials National Association of Drug Diversion Investigators National Athletic Trainers Association National Council for Behavioral Health National Independent Laboratory Association National Safety Council Shatterproof The Gerontological Society of America Verde Technologies Page 5 of 5